Loading...
NASDAQ: ONCY
Oncolytics Biotech Inc.
Healthcare · Biotechnology
Market Cap
$95.39M
52w High
$1.51
52w Low
$0.33
P/E
-3.75
Volume
316.33K
Outstanding Shares
100.36M
Company profile
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
CEOJared Kelly
SectorHealthcare
IndustryBiotechnology
Employees28
IPO dateOct 5, 2001
Valuation
Forward P/E—
EV/EBITDA-2.45
Enterprise value$85.63M
Stock splits
May 25, 20182:19
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-530%▼610.46%vs FY2023
Analyst consensus
RatingBuy
Target price—
8
Buy
2
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 20, 2026
View
EPS
Actual vs estimate by quarter
Q1FY25
ActualEst.
-$0.06
-$0.09
Q3'25
ActualEst.
-$0.05
-$0.11
Q4'25
ActualEst.
-$0.10
-$0.12
Q2FY25
Next Est.
—
Revenue
Actual vs estimate by quarter
Q1FY25
ActualEst.
—
—
Q3'25
ActualEst.
—
—
Q4'25
ActualEst.
—
—
Q2FY25
Next Est.
—